To read the full article sign up for free or sign in.

Synairgen stock rockets as inhaled interferon-beta shows signs of efficacy in COVID-19

July 20, 2020

DUBLIN – Synairgen plc has detected what appear to be promising efficacy signals in a phase II trial of its inhaled formulation of interferon-beta 1a, SNG-001, in hospitalized COVID-19 patients.

BioWorld BioWorld MedTech Clinical Coronavirus Combination drug-device

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Illustration of female reproductive system with polycystic ovary

First atlas of the endometrium with polycystic ovary syndrome

BioWorld Science

Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial dysfunction in women who have hormonal...

Another rebound as Sangamo inks $1.4B capsid deal with Lilly

BioWorld

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an...